Archive | Clinical Trials

Survival Advantage With Drug Combination Confirmed in Subset of Patients With Melanoma

Patients with BRAF-positive advanced melanoma saw a 30 percent reduced risk of death with the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib), compared to treatment with Zelboraf alone, according to the final survival analysis of the phase 3 coBRIM study published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials, Clinical Trials

Immunotherapy Combination Demonstrates Benefit in Small, Early Trial of Melanoma

Patients with advanced melanoma saw evidence of clinical benefit with the combination of the oncolytic virus Imlygic (talimogene laherparepvec; T-VEC) and Keytruda (pembrolizumab). The combination also demonstrated an acceptable safety profile when the treatment regimen was administered at full doses, according to the results of a phase 1b study.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Examining the Impact of Opdivo’s Expanded Approval in Melanoma

The FDA granted an expanded approval to Opdivo (nivolumab) as a single agent and in combination with Yervoy (ipilimumab) on January 23 for the treatment of patients with melanoma who harbor BRAF V600 mutations. As a result of the expansion, Opdivo is now available as a frontline treatment for all patients with advanced melanoma, regardless […]

Read the full story

Posted in Patients Resources, FDA, Cancer in the News, Clinical Trials

Vitamin B3 derivative cuts risk of new skin cancers

A year of treatment with nicotinamide, a form of vitamin B3, significantly lowered the risk of common, non-melanoma skin cancer in high-risk patients, according to University of Sydney research published today in the New England Journal of Medicine.

Read the full story

Posted in Health Professionals, Patients Resources, Clinical Trials, Journals,Papers & Reports

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories